Dr Lee on the Antitumor Activity of Rinatabart Sesutecan in FRα+ Platinum-Resistant Ovarian Cancer

Elizabeth Lee, MD, discusses the efficacy of rinatabart sesutecan in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

“There were…a total of 4 CRs, 2 of which are pending confirmation. With the longer duration of follow-up… the median DOR has still not yet been reached. We’re very, very encouraged by the findings so far.”

Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute, discusses results from the dose-expansion cohort B1 of the phase 2 RAINFOLTM-01 trial (NCT05579366) evaluating the novel folate receptor alpha (FRα)–targeted antibody-drug conjugate rinatabart sesutecan (Rina-S; PRO1184) for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.